Overview

For the treatment of infantile spasms, or seizures, in infants and children under two years old, a Corticotropin repository injection is administered. It is also used in adult patients with relapsing types of multiple sclerosis (MS) or a disease of the central nervous system (CNS, which includes the brain and spinal cord. Although this drug does not treat MS, it may be able to lessen some of its crippling symptoms and lower the frequency of relapses that are connected to the illness. It is also used to treat certain allergies, skin conditions, eye conditions, and bone-related issues. The United States Food and Drug Administration (USFDA) approved the Corticotropin repository injection in 1952.

Drug Group:

The Corticotropin repository injection is a member of the hormone drug class. Regulating immune system activity successfully cures various illnesses and lowers the risk of organ damage caused by immunologically mediated processes.

Available Doses and Dosage Forms:

For treating multiple sclerosis, it is advised to administer daily injectable dosages of 80 to 120 units for two to three weeks. A chronic dosage of more than 40 daily units may result in uncontrollable side effects. Both intramuscular (IM) and subcutaneous (SC) administration of this medication are possible. Before administration, parenteral medication products should be visually inspected for discoloration and particulate matter.

For Patients

How Does Repository Corticotropin Injection Work?

Corticotropin-releasing hormone injection stimulates the adrenal cortex, releasing cortisol, corticosterone, aldosterone, and several mildly androgenic compounds. Many neurologists believe that intravenous administration of high-dose corticosteroids is the most effective method for treating exacerbations of multiple sclerosis (MS). Nonetheless, different practitioners may follow different precise guidelines when using the medication.

What Are the Things to Inform the Doctor Before Taking Repository Corticotropin Injection?

Patients should inform their doctor and pharmacist about any allergies they may have. This goes especially for allergies to the Corticotropin repository injection, other drugs, and other injectable ingredients, such as porcine (pig) proteins.
All prescription and over-the-counter drugs, vitamins, herbal remedies, and supplements, including diuretics (water pills), that a patient intends to take should be disclosed. The doctor can use this information to adjust medication dosage or monitor possible adverse effects.
Suppose a patient has any of the following medical conditions. In that case, they should let the doctor know if they have scleroderma (an inflammatory connective tissue disease that is persistent and characterized by skin and other tissue thickening and hardening), osteoporosis (a bone disease that appears when bone mass and mineral density decrease), systemic fungal infections, ocular herpes infection (infection of the eye caused by herpes simplex virus), heart failure, high blood pressure, diseases of the adrenal glands, recent surgeries, or a history of stomach ulcers. Additionally, caregivers must inform the doctor if a baby has an infection before or during delivery.
The patient must inform the physician if they suspect they have an infection, fever, cough, vomiting, diarrhea, flu-like symptoms, or any other symptoms. They must also inform if they have information that someone in the family is ill. Inform the doctor if the patient has tuberculosis (TB), a serious lung infection, or if they have ever had a positive skin test for TB. Also, please inform them if the patient has been exposed to TB. Additionally, let the doctor know if the patient currently has diabetes, an underactive thyroid gland, disorders of the nerves or muscles, such as myasthenia gravis (an autoimmune condition that results in muscle weakness), problems with the stomach or intestines, emotional issues, psychosis (difficulty in recognizing reality), liver or kidney disease, or any other conditions.
If a patient is nursing a child, planning to become pregnant, or is already pregnant, they should inform their doctor. It is advised to notify the physician if they become pregnant while using Corticotropin repository injection.
Patients should disclose the use of Corticotropin repository injection to the medical staff before surgery or emergency care. Wear a bracelet or carry a card with this information in an emergency.
Vaccinations should only be administered to patients after first talking to the doctor. If any family members are due for immunizations while receiving Corticotropin repository injection treatment, please notify the doctor as well.

Patients need to be informed that regular blood pressure monitoring by a physician is important and that their blood pressure may rise with Corticotropin repository injection treatment.
Additionally, using Corticotropin repository injection may increase the risk of infection. Patients should wash their hands frequently throughout treatment and avoid contact with people who are sick.

How Is Repository Corticotropin Injection Used?

Corticotropin repository injection is a long-acting gel that can be injected subcutaneously or intramuscularly. If it is used to treat infantile spasms, it is typically administered twice daily into a muscle for two weeks, followed by a gradual reduction in dosage over an additional two weeks. varies from once every 24 to 72 hours. It is critical to administer the Corticotropin repository injection as directed at regular intervals each day. It is imperative to adhere precisely to the prescribed dosage schedule and avoid altering it without contacting a physician.
Injections of the Corticotropin repository can be self-administered by patients, or they might ask a friend or family member for assistance. The patient or the person giving the injection must carefully read the manufacturer's instructions before giving the first injection at home. Medical professionals will explain the injection techniques, and they may also arrange for a nurse to visit the patient at home to demonstrate the procedure.
Corticotropin injections involve the use of a needle and syringe, and patients should check with their physician to establish which kind is best for them. Needles and syringes must be used only once. It should never be shared. Needles and syringes must be disposed of in a puncture-proof container using proper protocol after use.
The upper arm, upper thigh, or stomach region, excluding the navel and the 1-inch region surrounding it, can all be used as injection sites for Corticotropin repository injections given subcutaneously. Adults should administer intramuscular injections in the upper arm or upper outer thigh. For infants, it should be administered in the upper outer thigh. A different location should be chosen for each injection, at least one inch apart from the sites used for the prior ones.
It is not advisable to inject into places that are red, swollen, painful, hard, or sensitive or that include scars, birthmarks, tattoos, or warts. It is best to avoid injecting into the groin or knee regions.
Scrutinize the Corticotropin repository injection vial before preparing the dose. The drug should be free from particles, cloudiness, or discoloration; it should appear colorless and clear. Let the drug come to room temperature before injecting it.
It can be done by either holding the vial under the arm for a few minutes or rolling it gently between the hands.
A child can lie flat or be held on the caregiver's lap while receiving a Corticotropin repository injection. Having a second person help hold the kid steady or divert their attention using a toy while the injection is being administered could be advantageous. Before or after the injection, caregivers may put an ice cube on the injection site to help reduce the child's discomfort.
When a child receives a Corticotropin repository injection to treat infantile spasms, the physician or pharmacist will offer the caregiver a copy of the manufacturer's patient information sheet, also known as the medication guide, at the beginning of therapy and with every refill.

Dietary Instructions:

During Corticotropin repository injection treatment, patients may receive dietary advice from their physician, emphasizing low-sodium or high-potassium intake. Furthermore, the physician might suggest consuming a potassium supplement. Patients should consult their physician for further advice and details on dietary suggestions and supplementation.

Side Effects:

If a patient has any of the following side effects from the Corticotropin repository injection, they should inform their doctor immediately because they could get worse or persist:

Alterations in appetite.
Gaining weight.
Alterations in mood or personality.
Irritability.
Unusual excitement.

During or after Corticotropin repository injection treatment, people should call their doctor right away if they experience any of the following symptoms or seek emergency medical help.

Fever, cough, vomiting, diarrhea, sore throat, or other infection-related symptoms.
Open wounds or lesions.
Facial swelling or puffiness.
Fat accumulation around the neck (not in the legs or arms).
Skin becomes thin.
Breasts, thighs, and abdomen have stretch marks.
Bruises.
Weakness of the muscle.
Stomach ache.
Vomit with blood, or that resembles coffee grounds.
Vision issues.
Depression.
Breathing difficulty.
Heartbeat increases.
Rashes.
Increased thirst.
Difficulty in reality recognition.
Swelling in the neck, lips, tongue, or face.

Corticotropin repository injection may slow children's growth and development; thus, pediatricians should regularly monitor their development. Additionally, due to the increased risk of osteoporosis, doctors may recommend bone density scans as part of the treatment. Patients should discuss these concerns with their doctor and explore ways to reduce the risk of osteoporosis.

Missed Dose:

If a Corticotropin repository injection dose is missed, administer it as soon as possible.

Overdose:

Corticotropin repository injection overdose can result in several potentially dangerous side effects, especially when high amounts are exposed over an extended period. It is noteworthy that compared to regular dosing, a single high dose or even several big doses is not anticipated to have appreciable side effects. Clinical research and published literature have not revealed any instances of Corticotropin repository injection-related fatalities or acute overdose symptoms.

Furthermore, an unintentional acute overdose is unlikely to happen while administering the medication intramuscularly.

Supply and Storage:

To ensure safety, the Corticotropin repository injection should be refrigerated, properly sealed, and kept out of children's access in its original container. To avoid unintentional intake, unused prescription drugs should be disposed of appropriately. It is advised against flushing drugs down the toilet. Alternatively, people can seek advice on proper disposal techniques from their pharmacist, the local waste/recycling department, or medication take-back programs. Use child-resistant containers to keep all medications out of reach and sight of youngsters. Medication should be kept out of children's reach and in a secure area with safety caps locked.

For Doctors:

Indication

Multiple Sclerosis - Adults with acute exacerbations of multiple sclerosis may receive approval for managing MS with Corticotropin repository injection. Trials under control have demonstrated the effectiveness of this approach in accelerating the resolution of these exacerbations. Nevertheless, there is no evidence that corticotropin repository injection affects the disease's course or ultimate outcome.
Infantile Spasms - Injections of the Corticotropin repository are specifically recommended as a monotherapy to treat infantile spasms in newborns and young children under the age of two.
Rheumatic Disease - Corticotropin repository injection is used as supplemental therapy for the short-term management of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis to address acute episodes or exacerbations:
Collagen Disease - Corticotropin repository injection is used as maintenance therapy or during exacerbations in some instances of polymyositis and systemic lupus erythematosus.
Respiratory Disease - Sarcoidosis.
Edematous State - Corticotropin repository injection is used to induce diuresis or relieve proteinuria in nephrotic syndrome patients who do not have uremia, especially in idiopathic or lupus erythematosus instances.
Allergic Condition - Serum sickness.
Ophthalmic Conditions - Severe acute and chronic allergies and inflammatory diseases affecting the eye and surrounding structures are treated with Corticotropin repository injection.

Contraindication:

Corticotropin repository injection should not be used in the following situations:

Intravenous delivery.
Children with probable congenital infections under the age of two.
Concurrent administration of Corticotropin repository injection at levels that suppress the immune system in individuals undergoing live or live-attenuated vaccinations.
Patients suffering from congestive heart failure, uncontrolled hypertension, scleroderma, osteoporosis, ocular herpes simplex, systemic fungal infections, recent surgery, peptic ulcer history or presence, adrenocortical hyperfunction, primary adrenocortical insufficiency, or sensitivity to porcine-derived proteins.

What Are the Pharmacological Aspects of Repository Corticotropin Injection?

Description

Corticotropin repository injection is composed of a complex blend of pituitary peptides and naturally occurring adrenocorticotropic hormone (ACTH) analogs. First, a low-ACTH-containing pig (porcine) pituitary extract is manufactured into a mixture with modified porcine ACTH and similar peptide analogs solubilized in gelatin. Porcine ACTH deamidated by N-25 is a significant ingredient in the mixture.

Corticotropin repository injection is provided in a sterile formulation containing 16 percent gelatin, enabling extended release following subcutaneous or intramuscular injection. It also contains 0.5 percent phenol, a small amount of cysteine (added), and water for injection, along with sodium hydroxide or acetic acid to adjust the pH.

Mechanism of Action

Elevated cortisol levels inhibit the release of endogenous ACTH (adrenocorticotropic hormone), which is controlled by the neurological system and feedback processes. Although cyclic AMP (adenosine monophosphate) is implicated, the entire degree of Corticotropin repository injection actions on the adrenal cortex remains unclear despite its binding to melanocortin receptors. There is still uncertainty regarding the Corticotropin repository injection mode of action while treating infantile spasms.

Pharmacokinetics

The pharmacokinetics of corticotropin repository injection are poorly understood; its half-life is unknown, and it rapidly disappears from circulation. Adrenocortical secretion increases linearly with continuous treatment. Toxicity (Carcinogenesis, Mutagenesis, and Infertility): Further comprehensive animal research is required. It is imperative to stress, nonetheless, that human use has not been linked to an increased incidence of cancerous disease.

Clinical Trials

The purpose of this multicenter, double-blind, placebo-controlled trial was to evaluate the safety and effectiveness of Repository Corticotropin injection (RCI) in patients with multiple sclerosis (MS) who relapsed after receiving an insufficient response to high-dose corticosteroids. More notable gains were found with RCI, according to qualitative evaluations conducted. Significantly, no fatalities or severe adverse events were recorded, indicating that RCI is a safe and useful treatment option for MS patients who relapse and do not respond well to high-dose corticosteroids.

Warnings and Precautions

The primary cause of the negative side effects of Corticotropin repository injection is due to its steroidogenic properties. Not all of the adverse events listed have been seen after using this medication, although they are expected to happen at some point.

Infection - The injection of the Corticotropin repository may increase the risk of infection by several pathogens, including bacteria, fungi, viruses, protozoa, or helminths. Close observation is necessary for patients who have latent tuberculosis or positive tuberculin reactivity. Chemoprophylaxis may be required in patients undergoing protracted therapy.

Cushing Syndrome and Adrenal Insufficiency Upon Withdrawal - Cushing's syndrome and suppression of the hypothalamic-pituitary axis (HPA) are possible side effects of H.P. Acthar Gel treatment. Patients under this medication for an extended period should be closely watched. Adrenal insufficiency symptoms, like weight loss, weakness, and low blood pressure, may occur when the medicine is stopped.
Vaccination - Live or live attenuated vaccinations should not be administered to individuals taking Corticotropin repository injection immunosuppressive doses because of the potential for side effects. Vaccines that have been killed or rendered inactive may be given, but their efficacy cannot be assured. Other vaccination protocols should be handled carefully because they risk neurological problems and a lack of antibody response, especially when high dosages are involved.

Masking Symptoms of Other Diseases - Corticotropin repository injection frequently hides the signs and symptoms of underlying illnesses without changing the course of those conditions. Patients should be closely watched for indications of infection, changes in body weight, irregular heartbeat, hyperglycemia, hypertension, and fecal blood loss during and after therapy termination.

Gastrointestinal Bleeding and Perforation - Corticotropin repository injection may cause stomach ulcers and gastrointestinal (GI) bleeding. Individuals with specific gastrointestinal conditions are more likely to experience perforation. Therapy may mask symptoms, such as peritoneal irritation, that indicate gastrointestinal perforation. In cases of imminent perforation, abscess, diverticulitis, pyogenic infections, recent intestinal surgery, and active or latent peptic ulcers, caution should be used.

Behavioral and Mood Disturbances - The central nervous system effects of Corticotropin repository injection might range from euphoria to insomnia to irritability (particularly in babies), mood swings, to personality changes, to severe depression, to psychotic symptoms. Furthermore, psychotic tendencies or emotional instability that already exist could get worse.

Comorbid Conditions - Patients who already have comorbid disorders may get worse if Corticotropin repository injection is prescribed to them. It is urged that individuals exercise caution, especially those with myasthenia gravis and diabetes.

Ophthalmic Effects - Long-term use of Corticotropin repository injection may cause glaucoma and posterior subcapsular cataracts, which can damage the optic nerve. Prolonged use may also raise the possibility of developing secondary viral and fungal eye infections.

Immunogenicity Potential - Since Corticotropin repository injection is immunogenic, findings suggest that with long-term administration, patients may acquire antibodies against it, which could reduce endogenous ACTH and Corticotropin repository injection activity. Extended usage could raise the possibility of hypersensitive reactions. Before beginning medication, patients should have their sensitivity to pig protein assessed. Throughout treatment, symptoms should be closely watched for.

Hypertension, Hypokalemia, and Retention of Salt and Water - Corticotropin repository injection can increase calcium and potassium excretion, raise blood pressure, and promote salt and water retention. Restricting salt in the diet and taking potassium supplements can be necessary. Patients with congestive heart failure, hypertension, or renal insufficiency should be treated cautiously.

Decrease in Bone Density - Because Corticotropin repository injection alters osteoblast function and calcium regulation, it may cause a decrease in bone production and a rise in bone resorption. This can impede bone development in children and adolescents and cause osteoporosis in people of any age, along with reduced sex hormone production and a diminished protein matrix in bones. Before beginning treatment, patients who are at a greater risk of osteoporosis, like postmenopausal women, should be given extra care. Patients undergoing long-term therapy should have their bone density checked.

Use in Pregnancy - It has been demonstrated that Corticotropin repository injection has an embryocidal effect. Inform pregnant mothers, as it may endanger the fetus.

Negative Effects on Growth and Physical Development - In youngsters, long-term usage of Corticotropin repository injection may harm physical development and growth. During treatment, especially with greater doses or extended treatment durations, alterations to appetite are typical. However, when Corticotropin repository injection is stopped, these effects usually disappear. It is critical to keep a close eye on the physical growth and development of children undergoing protracted therapy.

Drug Interaction

There have not been any official studies on medication interactions with the Corticotropin repository injection. However, if combined with diuretic medication, it could worsen electrolyte loss.

Specific Considerations

Pregnancy - Since Corticotropin repository injection has been shown to have an embryocidal effect, it is classified as pregnancy class C. There is not enough thorough research material available regarding the impact on the health of pregnant women. It should only be used during pregnancy if the expected advantages outweigh the potential dangers to the developing fetus.
Lactation - It is unknown if Corticotropin repository injection is excreted in human milk. When treating a nursing woman, care must be taken since many medications are secreted in human milk and because nursing infants may experience severe adverse responses. When deciding whether to stop taking the medication or stop nursing, the risks and benefits to the mother and the child should be carefully considered.
Pediatric Patients - Data from clinical studies not supported by the manufacturer, as well as retrospective case reviews, were used to evaluate safety in children treated for infantile spasms. Although the adverse reactions observed in younger patients receiving treatment for infantile spasms are similar to those observed in older patients, there are some differences in their frequency and severity because of factors like the infant's very young age, the underlying disorder, the length of therapy, and the dosage regimen. Effects on growth are especially concerning. It is essential to emphasize that children may experience significant adverse effects that adults have experienced, underscoring the importance of careful monitoring and assessment in this population.

Repository Corticotropin Injection - An Overview